Last updated on August 2019

A Study of ASP2215 (Gilteritinib) by Itself ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy


Brief description of study

This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It is when bone marrow makes white blood cells that are not normal. These are called leukemia cells. Some patients with AML have a mutation, or change, in the FLT3 gene. This gene helps leukemia cells make a protein called FLT3. This protein causes the leukemia cells to grow faster.

For patients with AML who cannot receive standard chemotherapy, azacitidine (also known as Vidaza) is a current standard of care treatment option in the United States. This clinical study is testing an experimental medicine called ASP2215, also known as gilteritinib. Gilteritinib works by stopping the leukemia cells from making the FLT3 protein. This can help stop the leukemia cells from growing faster.

This study will compare two different treatments. Patients are assigned to one of these two groups by chance: a medicine called azacitidine, also known as Vidaza, or an experimental medicine gilteritinib in combination with azacitidine. There is a twice as much chance to receive both medicines combined than azacitidine alone. The clinical study may help show which treatment helps patients live longer.

Detailed Study Description

Patients considered an adult according to local regulation at the time of obtaining informed consent may participate in the study.

Safety Cohort Prior to initiation of the randomized trial, 8 to 12 patients will be enrolled to evaluate the safety and tolerability of ASP2215 given with azacitidine therapy in the study population.

Randomized Trial Approximately 323 patients will be randomized in a 2:1 ratio to receive ASP2215 plus azacitidine (Arm AC) or azacitidine only (Arm C).

Earlier protocol versions included a 1:1:1 randomization ratio to receive Arm A: ASP2215, Arm AC: ASP2215 + azacitidine or Arm C: azacitidine. Randomization to Arm A was removed in the current protocol version. Patients previously randomized to Arm A should continue following treatment and assessments as outlined in the protocol.

Patients will enter the screening period up to 14 days prior to the start of treatment. Patients will be administered treatment over 28-day cycles.

Clinical Study Identifier: NCT02752035

Find a site near you

Start Over

University of Southern California

Los Angeles, CA United States
  Connect »

University of Florida

Gainesville, FL United States
  Connect »

Orlando Health Inc - Clinic

Orlando, FL United States
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

Norton Cancer Institute

Louisville, KY United States
  Connect »

GHS Cancer Institute

Greenville, SC United States
  Connect »

Baylor Research Institute

Dallas, TX United States
  Connect »

LDS Hospital

Salt Lake City, UT United States
  Connect »

Site AU61012

Camperdown, Australia
  Connect »

Site AU61004

Liverpool, Australia
  Connect »

Site AU61008

Adelaide, Australia
  Connect »

Site AU61007

Geelong, Australia
  Connect »

Site BE32003

Bruxelles, Belgium
  Connect »

Site BE32007

Brussel, Belgium
  Connect »

Site BE32008

Montigny-le-Tilleul, Belgium
  Connect »

Site CA15009

Edmonton, AB Canada
  Connect »

Site CA15004

Halifax, NS Canada
  Connect »

Site CA15002

Toronto, ON Canada
  Connect »

Site CA15006

Montreal, QC Canada
  Connect »

Site FR33003

Nimes Cedex 09, France
  Connect »

Site FR33016

Limoges, France
  Connect »

Site FR33019

Montpellier Cedex 5, France
  Connect »

Site FR33001

Nantes cedex 01, France
  Connect »

Site FR33014

Vandoeuvre les Nancy, France
  Connect »

Site FR33023

Valenciennes, France
  Connect »

Site FR33013

Pierre-Benite, France
  Connect »

Site FR33017

Le Mans, France
  Connect »

Site FR33012

Poitiers, France
  Connect »

Site FR33020

Bayonne, France
  Connect »

Site FR33007

Le Chesnay Cedex, France
  Connect »

Site FR33004

Lille cedex, France
  Connect »

Site DE49002

Tuebingen, Germany
  Connect »

Site DE49007

Munchen, Germany
  Connect »

Site DE49005

Frankfurt, Germany
  Connect »

Site DE49015

Rostock, Germany
  Connect »

Site DE49012

Braunschweig, Germany
  Connect »

Site DE49004

Hannover, Germany
  Connect »

Site DE49009

Halle (Saale), Germany
  Connect »

Site DE49003

Berlin, Germany
  Connect »

Site DE49013

Heilbronn, Germany
  Connect »

Site DE49011

Stuttgart, Germany
  Connect »

Site IT39011

San Giovanni Rotondo, Italy
  Connect »

Site JP81027

Matsuyama, Japan
  Connect »

Site JP81010

Maebashi, Japan
  Connect »

Site JP81021

Fukuyama, Japan
  Connect »

Site JP81023

Kanazawa, Japan
  Connect »

Site JP81003

Yokohama, Japan
  Connect »

Site JP81032

Yokohama, Japan
  Connect »

Site JP81011

Kurashiki, Japan
  Connect »

Site JP81029

Shibuya-ku, Japan
  Connect »

Site JP81014

Shinagawa-ku, Japan
  Connect »

Site JP81022

Tachikawa, Japan
  Connect »

Site JP81005

Kumamoto, Japan
  Connect »

Site JP81004

Nagasaki, Japan
  Connect »

Site JP81017

Nagasaki, Japan
  Connect »

Site JP81026

Tokushima, Japan
  Connect »

Site KR82003

Namdong, Korea, Republic of
  Connect »

Site KR82013

Seoul, Korea, Republic of
  Connect »

Site KR82008

Seoul, Korea, Republic of
  Connect »

Site KR82006

Seoul, Korea, Republic of
  Connect »

Site KR82002

Seoul, Korea, Republic of
  Connect »

Site KR82001

Ulsan, Korea, Republic of
  Connect »

Site KR82014

Busan, Korea, Republic of
  Connect »

Site KR82010

Hwasun-gun, Korea, Republic of
  Connect »

Site KR82012

Seoul, Korea, Republic of
  Connect »

Site PL48004

Warszawa, Poland
  Connect »

Site PL48001

Olsztyn, Poland
  Connect »

Site ES34007

Palma de Mallorca, Spain
  Connect »

Site ES34008

Barcelona, Spain
  Connect »

Site ES34004

Barcelona, Spain
  Connect »

Site ES34010

Barcelona, Spain
  Connect »

Site ES34009

Barcelona, Spain
  Connect »

Site ES34005

Valencia, Spain
  Connect »

Site ES34012

Valladolid, Spain
  Connect »

Site TW88604

Kaohsiung, Taiwan
  Connect »

Site TW88605

Kwei Shan Hsiang, Taiwan
  Connect »

Site TW88607

Taichung, Taiwan
  Connect »

Site GB44004

London, United Kingdom
  Connect »

Site GB44007

Sheffield, United Kingdom
  Connect »

Site KR82015

Seongnam-si, Korea, Republic of
  Connect »